UnitedHealth Group has remained a subject of active institutional attention through mid-2026, according to multiple briefings covering the period. The company operates across managed care, pharmacy benefits, and health services segments and has drawn continued scrutiny amid a broader environment of elevated healthcare costs and an active regulatory environment [Brief - 2026-07-27] [Brief - 2026-07-19] [Brief - 2026-07-11]. A separate macro development — escalating military tensions around the Strait of Hormuz — drove broader equity markets lower during the European session on 16 July 2026, providing additional context for institutional activity across large-cap equities during this period [Brief - 2026-07-16].
As of the quarter ended 31 March 2026, UnitedHealth Group reported trailing twelve-month revenue of approximately $449.7 billion, reflecting year-over-year revenue growth of approximately 1.96%. Net income on a TTM basis stood at approximately $12.8 billion, with a net margin of 2.85% and an operating margin of 4.19%. EPS growth on a year-over-year basis was 0.73%. The company carried $28.0 billion in cash against total debt of $77.9 billion. The reported price-to-earnings ratio was 31.28, with a market capitalisation of approximately $377.1 billion at the time of reporting [SEC 10-Q - UNH - 2026-03-31].
Institutional ownership data reveals material position changes across several notable filers in the most recent reporting period. Millennium Management added approximately 56% to its UNH position, while AQR Capital Management increased its holding by approximately 36%, and Soros Fund Management expanded its position by approximately 14% [SEC 13F - Millennium - Q2 2026] [SEC 13F - AQR Capital - Q2 2026] [SEC 13F - Soros Fund Mgmt - Q2 2026]. Conversely, Citadel reduced its position by approximately 19% and Tiger Global decreased its holding by approximately 17% [SEC 13F - Citadel - Q2 2026] [SEC 13F - Tiger Global - Q2 2026]. No insider transaction data was provided for this reporting period.
The prevailing macro backdrop as of the report date shows the 10-year US Treasury yield at 4.75% and the 2-year yield at 4.28%, producing a normal yield curve configuration [FRED DGS10] [FRED DGS2]. This report was generated in response to the material institutional position changes observed across multiple prominent filers during the most recent 13F reporting cycle.